Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.
July 16, 7:29 AM
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis…
July 16, 7:20 AM
Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA), which ended Thursday's session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday.
July 15, 5:17 PM
Alexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary Endpoint
July 15, 4:11 PM
– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
July 15, 8:07 AM
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
AstraZeneca Announced Receipt of Clearance from the European Commission for the Proposed Acquisition of Alexion
July 6, 5:21 AM
AstraZeneca's (NYSE: AZN) proposed acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has achieved an important step towards completion by having cleared the European Commission review.
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
July 2, 7:38 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
June 29, 8:17 AM
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28)